Fierce Biotech1 min read
saveBausch + Lomb and Celldex rocked by respective phase 2 flops
Bausch + Lomb and Celldex have independently reported phase 2 flops. While Celldex ended work in the indication in response to the setback, Bausch + Lomb noted numerical improvements and exploratory analyses to make the case for talks about entering phase 3.
comments(0)
5-min edit window · permanent after that